Vir Biotechnology Profit Margin

Vir Biotechnology (VIR) currently reports a profit margin of -61.03% as of September 2026. That compares with -3198.39% in the prior-year period — up 98.1% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Vir Biotechnology's profit margin history and peer comparisons.

Vir Biotechnology's profit margin increased from -3198.39% to -61.03% — a 98.1% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vir Biotechnology's profit margin of -61.03% is lower than the Healthcare sector average of 9.48%. That is roughly 743.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Vir Biotechnology's current -61.03% should be judged against Healthcare norms (sector average: 9.48%) and against VIR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -61.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Vir Biotechnology, and consider following VIR for alerts when major investors trade the stock.